ARL6IP1

ARL6IP1 is an endoplasmic reticulum integral membrane protein that shapes high-curvature ER tubules through reticulon-like short hairpin transmembrane domains, constricting liposomes into tubules in vitro and binding directly to the ER-network GTPase atlastin to support the tubular ER (PMID:24262037). Beyond ER morphogenesis, it localizes to mitochondria-associated membranes where it directly binds LC3B and BCL2L13 to maintain ER–mitochondria homeostasis, and its loss drives dysregulated autophagy, mitochondrial dysfunction, and neuronal cell death, with knockout mice developing corticospinal demyelination and neuroinflammation (PMID:37934410). ARL6IP1 also acts as a negative regulator of apoptosis, inhibiting caspase-9 activity downstream of cytochrome c release without blocking the release or cleavage events themselves (PMID:12754298), and its protein abundance is sustained by HuD (ELAVL4)-mediated stabilization of ARL6IP1 mRNA under stress (PMID:35012594). Additional functions include promoting EAAC1-mediated glutamate transport through a PKC-dependent heterodimer with addicsin/ARL6IP5 (PMID:18684713) and modulating BACE1 translation by interacting with the RNA-binding protein FXR1 at the BACE1 5'UTR (PMID:37216506).

1. 2000 Low

   Established the basic subcellular residence of ARL6IP1, framing it as a membrane-associated protein before any function was known.

   Evidence Immunofluorescence microscopy localizing the protein to intracytoplasmic membranes

   PMID:10995579

   Open questions at the time

   • Single localization experiment with no functional consequence linked
   • Did not resolve which membrane compartment (ER vs other)
2. 2003 Medium

   Answered whether ARL6IP1 has a role in cell death by showing it is an apoptosis inhibitor acting at a defined point in the caspase cascade.

   Evidence Inducible overexpression with fluorogenic caspase-9 substrate and cytochrome c release assays across multiple apoptotic stimuli

   PMID:12754298

   Open questions at the time

   • No direct binding partner identified that mediates caspase-9 inhibition
   • Single lab, no structural or reconstitution validation
   • Mechanism by which it blocks caspase-9 activity without affecting cleavage unresolved
3. 2008 High

   Identified a discrete protein partner (addicsin/ARL6IP5) and showed the interaction tunes glutamate transporter affinity, linking ARL6IP1 to neurotransmission.

   Evidence Reciprocal co-IP, glutamate transport kinetics (Km/Vmax), PKC activation, and binding-region mutagenesis

   PMID:18684713

   Open questions at the time

   • Physiological context of EAAC1 regulation in vivo not established
   • How PKC dependence couples to the heterodimer unresolved
4. 2012 Medium

   Probed developmental requirements by loss-of-function in zebrafish, linking arl6ip1 to neural crest migration/specification and to cilia-dependent Shh signaling.

   Evidence Morpholino knockdown with in situ marker analysis and TUNEL apoptosis assays

   PMID:22427906

   Open questions at the time

   • Cilia defect inferred rather than directly demonstrated
   • Molecular link between ER-shaping function and Shh signaling not defined
   • Morpholino approach without genetic mutant confirmation
5. 2012 Medium

   Extended the developmental role to cell-cycle control, showing arl6ip1 is required for retinal progenitor cell-cycle exit.

   Evidence Morpholino knockdown with FACS DNA content, BrdU, phospho-H3, and p57kip2 rescue

   PMID:22269635

   Open questions at the time

   • Mechanistic connection between ARL6IP1 and cyclin D1/p57kip2 regulation unknown
   • Whether effect is cilia/Shh-mediated not directly tested
6. 2013 Medium

   Resolved membrane topology and mapped a chemical (conophylline) binding domain, providing a structural handle on the protein.

   Evidence Topological analysis in cells with deletion mutagenesis and biotinyl-CNP affinity pulldown

   PMID:24076029

   Open questions at the time

   • Functional consequence of CNP binding not established in this study
   • Three-spanning topology reported alongside other four-TM descriptions
7. 2014 High

   Defined the core molecular activity: ARL6IP1 is a membrane-shaping ER protein that generates tubules and partners with atlastin.

   Evidence In vitro liposome constriction, ER tubule induction, microtubule-independence, hairpin domain mutagenesis, and co-IP with atlastin

   PMID:24262037

   Open questions at the time

   • Stoichiometry/structure of the ARL6IP1–atlastin complex not resolved
   • How membrane-shaping relates to its apoptotic and transport roles unintegrated
8. 2022 Medium

   Connected ARL6IP1 abundance to post-transcriptional control, showing HuD stabilizes its mRNA to sustain anti-apoptotic protein levels.

   Evidence RIP-SEQ, synthetic RNA oligonucleotide capture, and recombinant HuD binding assay

   PMID:35012594

   Open questions at the time

   • Functional anti-apoptotic consequence inferred rather than directly reconstituted
   • Binding site on ARL6IP1 mRNA not mapped
9. 2023 High

   Placed ARL6IP1 at mitochondria-associated membranes with two direct partners (LC3B, BCL2L13), linking it to autophagy, mitochondrial homeostasis, and a neurological KO phenotype.

   Evidence MAM fractionation, reciprocal co-IP, KO mouse histopathology, neuronal differentiation siRNA, and gene therapy rescue

   PMID:37934410

   Open questions at the time

   • How ER-shaping activity mechanistically drives the MAM/autophagy function unresolved
   • Whether LC3B and BCL2L13 binding occur in the same complex unknown
10. 2023 Medium

    Revealed a translational-regulation role, showing ARL6IP1 interacts with FXR1 to suppress BACE1 translation and amyloidogenesis under conophylline treatment.

    Evidence RNA pulldown-MS, co-IP, 5'UTR luciferase reporter, and APP/PS1 in vivo cognitive assessment

    PMID:37216506

    Open questions at the time

    • Direct RNA binding by ARL6IP1 vs indirect via FXR1 not fully separated
    • Single lab; relationship to its ER membrane function unclear
11. 2026 Low

    Implicated ARL6IP1 in cancer metabolism via OLFM4, placing it upstream of glycolytic regulation in breast cancer cells.

    Evidence Co-IP with OLFM4, ECAR/glucose/lactate assays, and OLFM4 overexpression rescue

    PMID:40444622

    Open questions at the time

    • Single Co-IP with only partial pathway rescue, no reconstitution or structural validation
    • Direct vs indirect interaction unresolved
    • Generality beyond one breast cancer model untested

• How ARL6IP1's ER tubule-shaping activity mechanistically unifies its diverse roles in apoptosis suppression, MAM/autophagy regulation, glutamate transport, and translational control remains unresolved.
• No integrated structural model connecting membrane-shaping to its protein/RNA partner functions
• Whether distinct activities reflect separate domains or compartment-specific pools is unknown